{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001919246","name":"Pelthos Therapeutics Inc.","summary":"Pelthos Therapeutics Inc. is a bio-pharmaceutical company focused on commercializing FDA-approved dermatology products. Its portfolio includes ZELSUVMI (berdazimer gel, 10.3%) for molluscum contagiosum, XEPI (ozenoxacin cream, 1%) for impetigo, and XEGLYZE (abametapir) for head lice. Formed via the July 2025 merger of Channel Therapeutics Corporation and LNHC, Inc., the company also holds clinical-stage assets targeting the NaV1.7 sodium ion-channel for pain and maintains a manufacturing facility for its NITRICIL technology platform.","people":[],"products":[{"name":"ZELSUVMI (berdazimer gel, 10.3%)","type":"platform","description":"First FDA-approved topical nitric oxide-releasing prescription gel for molluscum contagiosum in patients one year of age and older; launched July 2025."},{"name":"XEPI (ozenoxacin cream, 1%)","type":"platform","description":"FDA-approved non-fluorinated quinolone antimicrobial cream for topical treatment of impetigo in adults and pediatric patients two months and older; acquired November 2025."},{"name":"XEGLYZE (abametapir)","type":"platform","description":"FDA-approved prescription pediculicide for topical treatment of head lice infestation in patients six months of age and older; acquired December 2025."},{"name":"NITRICIL Technology Platform","type":"platform","description":"Proprietary nitric oxide-based technology platform used to develop ZELSUVMI; enables stable, tunable delivery of nitric oxide for therapeutic applications."}],"partnerships":[{"partner_name":"Ligand Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Exclusive license and sublicense agreement granting Pelthos rights to NITRICIL IP and ZELSUVMI commercialization worldwide except Japan; master services agreement for API supply.","start_date":null},{"partner_name":"Ferrer Internacional S.A.","partnership_type":"licensing","description":"Exclusive license agreement related to U.S. commercialization rights of XEPI (ozenoxacin cream, 1%).","start_date":null},{"partner_name":"Interquim, S.A.U.","partnership_type":"licensing","description":"Party to exclusive license agreement related to U.S. commercialization rights of XEPI alongside Ferrer Internacional.","start_date":null},{"partner_name":"Horizon Technology Finance Corporation","partnership_type":"strategic","description":"Venture Loan and Security Agreement providing senior secured term loan facility of up to $50.0 million to support commercialization and general corporate purposes.","start_date":null},{"partner_name":"Hatchtech Pty Ltd.","partnership_type":"licensing","description":"Acquisition of XEGLYZE from this Australian biotech company, providing worldwide commercialization rights to the head lice treatment.","start_date":null},{"partner_name":"Biofrontera, Inc.","partnership_type":"licensing","description":"Acquired U.S. commercialization rights to XEPI from Biofrontera in November 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"82b4b710d38cb92a3ff103246f7a174d84a84dc301c32022830887a6e4f43954","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"24f6c7fb2bc17f1e9385da7981d98d67ea21fe5830f461fdfdbb5a6350c453d5","parent":"82a0abe6aa7766d77762a55345886685a573c68d869801e9b9edc68080b67cfe","source":"0001919246-26-000013","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":59,"hourly_limit":500,"remaining":441,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}